In HNSCC, activation of the NRF2–ARE pathway has been shown to protect cells from GPX4 inhibition, while blockade of this pathway restores susceptibility to ferroptosis [52]. This evidence concerns the gene GPX4 and head and neck squamous cell carcinoma.